Opinion

Podcast

Protecting Cardiorenal Function in Diabetic Kidney Disease

Experts discuss the intricate relationship between diabetes, kidney disease, and cardiovascular function and explore the evolving landscape of therapies with cardiorenal benefits.

To watch the video series component of this episode, click here.

1:27 Diabetes, kidney disease, and CV risk interrelationship

3:54 Expanding indications for SGLT2 inhibitors for CV risk reduction

5:40 CV benefits of SGLT2 inhibitors in clinical trials

7:20 Use of finerenone for CKD

9:20 Using stage and severity of CKD to guide treatment choice

14:00 Benefits of combining finerenone with SGLT2 inhibitors

16:30 Potential use of GLP 1 agonists for CKD

19:20 Considerations for incorporating therapies for CKD

23:00 Key takeaways on using new treatments for CKD

Related Videos
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Rahul Aggarwal, MD | Credit: LinkedIn
Kenneth Mahaffey, MD | Credit: Stanford University
MEDcast logo
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.